US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer.

Shord, Stacy S; Zhu, Hao; Liu, Jiang; Rahman, Atiqur; Booth, Brian; Zineh, Issam

Shord, Stacy S; Zhu, Hao; Liu, Jiang; Rahman, Atiqur; Booth, Brian; Zineh, Issam.

Afiliação

Shord SS; Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Zhu H; Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
Liu J; Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
Rahman A; Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Booth B; Division of Cancer Pharmacology I (DCPI), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
Zineh I; OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.

CPT Pharmacometrics Syst Pharmacol ; 12(11): 1573-1576, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37641498

Assuntos

Neoplasias; Estados Unidos; Humanos; United States Food and Drug Administration; Neoplasias/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google